- Incannex Healthcare (IHL) has started a pre-clinical animal trial testing its IHL-216A drug for traumatic brain injury (TBI) and concussion
- TBI reportedly accounts for roughly 10 million hospitalisations or deaths annually
- Eight separate rodent cohorts will be given components or combinations of the drug to find optimal dosages for an upcoming human trial
- Data is set to contribute to Incannex’s Food and Drug Administration data package
- Company shares are up 5.71. per cent and are trading for 7.4 cents each
Incannex Healthcare (IHL) has started a pre-clinical animal trial investigating the capability of its IHL-216A drug for traumatic brain injury (TBI) and concussion.
Every year, TBI accounts for roughly 10 million deaths or hospitalisation around the world. There are currently no pharmaceutical agents that are approved to treat it.
Incannex previously filed a provisional patent over IHL-216A for TBI and concussion. IHL-216A is a combination drug comprising cannabidiol (CBD) and a halogenated volatile anaesthetic agent.
The trial will introduce rodents to head trauma which will be implemented in a highly-controlled environment to inflict a reproducible injury.
Eight groups of rodents will be administered parts or combinations of IHL-216A at varying doses soon after the trauma.
The rodents will go through behavioural tests to assess their neurocognitive and motor function. IHL will also monitor secondary injury and structural damage to the brain.
IHL’s drug discovery team believe IHL-216A may reduce neuro-excitation, neuro-inflammation, cerebral blood flow and cerebral oxygen consumption.
“IHL has embarked on a major and multifaceted program to give the company every chance to achieve FDA registration over up to 4 clinical assets,” CEO and Managing Director, Joel Latham said.
The data will help to inform an upcoming human trial and will contribute to Incannex’s Food and Drug Administration data package.
Company shares are up 5.71. per cent and are trading for 7.4 cents each at 11:22 am AEST.